Long-term treatment for congenital adrenal hyperplasia
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests the long-term safety and effectiveness of a medicine called asedebart for people with congenital adrenal hyperplasia (CAH) who have already been in a previous trial. It aims to see if continued treatment helps control hormone levels and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already taken asedebart in a previous clinical trial.
- You and your doctor agreed that continuing asedebart is a good option.
- If it's been more than 12 weeks since your last asedebart dose, you must be on a stable daily steroid dose of at least 8 mg per square meter (in hydrocortisone equivalents) for the past month.
- If it's been more than 12 weeks since your last dose, your current treatment may not be controlling your condition well, so you need to have either high androgen levels (A4 above normal) or be on a higher steroid dose (above 13 mg per square meter).
- You are not pregnant or breastfeeding, and if you could become pregnant, you are willing to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
This trial tests a new medicine (NBIP-01435) to see if it helps adults with classic congenital adrenal hyperplasia better manage their condition. The goal is to improve hormone levels and potentially allow for lower steroid doses.
This study tracks adults with congenital adrenal hyperplasia (a condition where the body can't make enough cortisol) who switch to a new form of hydrocortisone called modified-release. It looks at how well the medication works over time and its effects on daily life.
This study tests the long-term safety and effectiveness of the study drug atumelnant for people with congenital adrenal hyperplasia. It is for those who have already completed a previous atumelnant study and may benefit from continuing treatment.
Hear when a new Adrenal Hyperplasia, Congenital trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.